AbbVie (ABBV) Total Liabilities (2012 - 2026)

AbbVie (ABBV) has 15 years of Total Liabilities data on file, last reported at $143.1 billion in Q1 2026.

• Total Liabilities for Q1 2026 came in at $143.1 billion, up 6.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $143.1 billion (up 6.22% YoY), and the FY2025 annual result was $137.2 billion, up 4.09% from the prior year.
• Total Liabilities improved to $143.1 billion in Q1 2026 per ABBV's latest filing, from $137.2 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $143.1 billion in Q1 2026 and troughed at $121.2 billion in Q1 2023.
• A 5-year average of $131.1 billion and a median of $131.8 billion in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities decreased 7.38% in 2022, then rose 16.15% in 2024.
• A 5-year view of Total Liabilities shows it stood at $121.5 billion in 2022, then advanced by 2.3% to $124.3 billion in 2023, then advanced by 6.02% to $131.8 billion in 2024, then rose by 4.09% to $137.2 billion in 2025, then rose by 4.29% to $143.1 billion in 2026.
• Business Quant data shows ABBV's Total Liabilities at $143.1 billion in Q1 2026, $137.2 billion in Q4 2025, and $136.5 billion in Q3 2025.